To join this case, fill out the form below
Equillium, Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Equillium, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. (“Equillium” or the “Company”) (NASDAQ:EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR).  Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.

Weiss Law is investigating whether (i) Equillium’s board of directors acted in the best interests of Company shareholders in agreeing to the merger and (ii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Other Cases

June 26, 2024

Sharecare, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sharecare, Inc. (“Sharecare” or the “Company”) (NASDAQ:SHCR), in connection with its acquisition by Altaris, LLC. Under the merger agreement, the Company’s shareholders will receive $1.43 per share.

Join Case →

June 26, 2024

Alimera Sciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. (“Alimera” or the “Company”) (NASDAQ: ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company’s shareholders will receive $5.50 per share cash at closing and one non-tradable contingent value right (“CVR”) to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

Join Case →

June 7, 2024

PowerSchool Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PowerSchool Holdings, Inc. (“PowerSchool” or the “Company”) (NYSE: PWSC), in connection with its acquisition by Bain Capital, LP. Under the merger agreement, the Company’s shareholders will receive $22.80 per share. The transaction is valued at approximately $5.6 billion.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn